WATERTOWN, Mass.--(BUSINESS WIRE)--Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, announced ...
Non-human primate study results demonstrate improvements in skeletal and cardiac muscle delivery efficacy, safety potential, human translatability, and manufacturability over prior AAV capsids ...
Scientists have a new trick to tackle TDP-43: antibodies delivered via adeno-associated virus. In the September 3 Molecular Therapy, scientists led by Damien Nevoltris at AC Immune, Lausanne, ...
The MarketWatch News Department was not involved in the creation of this content. -- Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of ...
Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes Kits incorporate Thermo Fisher Scientific’s CaptureSelect affinity reagents for ...
HOUSTON and SYDNEY, Aug. 26, 2025 /PRNewswire/ -- PackGene Biotech, a global contract research organization (CRO) and contract development and manufacturing organization (CDMO) leader in ...
HOUSTON and SYDNEY, Aug. 26, 2025 /PRNewswire/ -- PackGene Biotech, a global contract research organization (CRO) and contract development and manufacturing organization (CDMO) leader in ...
Neovascular age-related macular degeneration (nAMD) is a progressive eye disease characterized by choroidal neovascularization and subretinal hemorrhage and exudation, leading to vision impairment.
Demand for adeno-associated viral (AAV) vectors is increasing as more and more cell and gene therapy firms use them to make products. In response, vector suppliers are embracing faster, more efficient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results